Zileuton, a Leukotriene Synthesis Inhibitor in the Management of Chronic Asthma. Clinical Pharmacokinetics and Safety

Overview

Journal Clin Rev Allergy Immunol

Specialty Allergy & Immunology

Date 1999 Aug 7

PMID 10436867

Citations 8

Authors

L M Dube

L J Swanson

W Awni

Affiliations

Soon will be listed here.

Citing Articles

Alpha-Lipoic Acid-Mediated Inhibition of LTB Synthesis Suppresses Epithelial-Mesenchymal Transition, Modulating Functional and Tumorigenic Capacities in Non-Small Cell Lung Cancer A549 Cells.

Torres M, Rios J, Valle A, Indo S, Gv K, Lopez-Moncada F Curr Ther Res Clin Exp. 2025; 102():100765.

PMID: 39816494 PMC: 11731977. DOI: 10.1016/j.curtheres.2024.100765.

New Zileuton-Hydroxycinnamic Acid Hybrids: Synthesis and Structure-Activity Relationship towards 5-Lipoxygenase Inhibition.

Chiasson A, Robichaud S, Moutombi F, Hebert M, Mbarik M, Surette M Molecules. 2020; 25(20).

PMID: 33066378 PMC: 7587396. DOI: 10.3390/molecules25204686.

Proinflammatory Pathways in the Pathogenesis of Asthma.

Peebles Jr R, Aronica M Clin Chest Med. 2019; 40(1):29-50.

PMID: 30691715 PMC: 6364573. DOI: 10.1016/j.ccm.2018.10.014.

Multi-Walled Carbon Nanotubes Augment Allergic Airway Eosinophilic Inflammation by Promoting Cysteinyl Leukotriene Production.

Carvalho S, Ferrini M, Herritt L, Holian A, Jaffar Z, Roberts K Front Pharmacol. 2018; 9:585.

PMID: 29922162 PMC: 5996183. DOI: 10.3389/fphar.2018.00585.

Side Effects of Leukotriene Receptor Antagonists in Asthmatic Children.

Erdem S, Nacaroglu H, Karkiner C, Gunay I, Can D Iran J Pediatr. 2015; 25(5):e3313.

PMID: 26495098 PMC: 4610338. DOI: 10.5812/ijp.3313.

References

Awni W, CAVANAUGH J, Witt G, Granneman G, Dube L . The effect of food on the pharmacokinetics of zileuton. Clin Pharmacokinet. 1995; 29 Suppl 2:62-6. DOI: 10.2165/00003088-199500292-00009. View

Braeckman R, Granneman G, Locke C, MACHINIST J, Cavannaugh J, Awni W . The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokinet. 1995; 29 Suppl 2:42-8. DOI: 10.2165/00003088-199500292-00007. View

Granneman G, Braeckman R, Locke C, CAVANAUGH J, Dube L, Awni W . Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet. 1995; 29 Suppl 2:77-83. DOI: 10.2165/00003088-199500292-00011. View

Awni W, CAVANAUGH J, Leese P, Kasier J, Cao G, Locke C . The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur J Clin Pharmacol. 1997; 52(1):49-54. DOI: 10.1007/s002280050248. View

Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T . Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol. 1995; 39(4):421-31. PMC: 1365131. DOI: 10.1111/j.1365-2125.1995.tb04472.x. View

Samuelsson B . Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983; 220(4597):568-75. DOI: 10.1126/science.6301011. View

Israel E, Rubin P, Kemp J, Grossman J, Pierson W, SIEGEL S . The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993; 119(11):1059-66. DOI: 10.7326/0003-4819-119-11-199312010-00001. View

Awni W, Locke C, Dube L, CAVANAUGH J . Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers. J Clin Pharmacol. 1997; 37(5):388-94. DOI: 10.1002/j.1552-4604.1997.tb04316.x. View

Lewis J . Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin Pharm. 1984; 3(2):128-38. View

10.

Awni W, Hussein Z, CAVANAUGH J, Granneman G, Dube L . Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans. Clin Pharmacokinet. 1995; 29 Suppl 2:92-7. DOI: 10.2165/00003088-199500292-00013. View

11.

Awni W, Braeckman R, CAVANAUGH J, Locke C, Linnen P, Granneman G . The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers. Clin Pharmacokinet. 1995; 29 Suppl 2:112-24. DOI: 10.2165/00003088-199500292-00016. View

12.

Israel E, Cohn J, Dube L, Drazen J . Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 1996; 275(12):931-6. View

13.

Awni W, Hussein Z, Granneman G, Patterson K, Dube L, CAVANAUGH J . Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet. 1995; 29 Suppl 2:67-76. DOI: 10.2165/00003088-199500292-00010. View

14.

Awni W, Braeckman R, Locke C, Dube L, Granneman G . The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. Clin Pharmacokinet. 1995; 29 Suppl 2:98-104. DOI: 10.2165/00003088-199500292-00014. View

15.

Awni W, Granneman G, Locke C, Brandwein S, Dube L . Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1995; 48(2):155-60. DOI: 10.1007/BF00192742. View

16.

Awni W, Wong S, Chu S, Patterson K, Hansen R, MACHINIST J . Pharmacokinetics of zileuton and its metabolites in patients with renal impairment. J Clin Pharmacol. 1997; 37(5):395-404. DOI: 10.1002/j.1552-4604.1997.tb04317.x. View

17.

Wong S, Awni W, CAVANAUGH J, Locke C, Dube L . The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers. Clin Pharmacokinet. 1995; 29 Suppl 2:9-21. DOI: 10.2165/00003088-199500292-00004. View

18.

Awni W, Braeckman R, Granneman G, Witt G, Dube L . Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. Clin Pharmacokinet. 1995; 29 Suppl 2:22-33. DOI: 10.2165/00003088-199500292-00005. View

19.

Liu M, Dube L, Lancaster J . Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol. 1996; 98(5 Pt 1):859-71. DOI: 10.1016/s0091-6749(96)80002-9. View

20.

Sarkar M, Jackson B . Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab Dispos. 1994; 22(6):827-34. View